Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
New England Journal of Medicine2013Vol. 368(23), pp. 2169–2181
Citations Over TimeTop 1% of 2013 papers
Christophe Legendre, Christoph Licht, Petra Muus, Larry A. Greenbaum, Sunil Babu, Camille L. Bedrosian, Coralie Bingham, D.J. Cohen, Yahsou Delmas, K. Douglas, Frank Eitner, Thorsten Feldkamp, Denis Fouque, Richard R. Furman, Osama Gaber, Maria Herthelius, Maryvonne Hourmant, Diana Karpman, Yvon Lebranchu, Christophe Mariat, Jan Menne, Bruno Moulin, Jens Nürnberger, Masayo Ogawa, Giuseppe Remuzzi, Tristan Richard, Rébecca Sberro‐Soussan, Beth Severino, N. Sheerin, Antonella Trivelli, Lothar Bernd Zimmerhackl, Tim Goodship, Chantal Loirat
Abstract
Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with atypical hemolytic-uremic syndrome. (Funded by Alexion Pharmaceuticals; C08-002 ClinicalTrials.gov numbers, NCT00844545 [adults] and NCT00844844 [adolescents]; C08-003 ClinicalTrials.gov numbers, NCT00838513 [adults] and NCT00844428 [adolescents]).
Related Papers
- → Eculizumab for Atypical Hemolytic Uremic Syndrome in Pregnancy(2013)72 cited
- → Eculizumab as First-Line Therapy for Atypical Hemolytic Uremic Syndrome(2014)24 cited
- Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function in Adult Atypical Hemolytic Uremic Syndrome (aHUS) Patients (Pts)(2013)
- → Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding(2019)5 cited
- → Successful Discontinuation of Eculizumab in a Pediatric Patient With Atypical Hemolytic Uremic Syndrome and Underlying Systematic Lupus Erythematosus(2022)1 cited